Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Efficacy and Safety of Calcipotriol Plus Betamethasone Dipropionate Gel Compared With Tacalcitol Ointment and the Gel Vehicle Alone in Patients With Psoriasis Vulgaris

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT00670241
Recruitment Status : Completed
First Posted : May 1, 2008
Results First Posted : March 8, 2011
Last Update Posted : April 14, 2015
Sponsor:
Information provided by (Responsible Party):
LEO Pharma

Tracking Information
First Submitted Date  ICMJE April 29, 2008
First Posted Date  ICMJE May 1, 2008
Results First Submitted Date  ICMJE November 23, 2010
Results First Posted Date  ICMJE March 8, 2011
Last Update Posted Date April 14, 2015
Study Start Date  ICMJE April 2008
Actual Primary Completion Date February 2009   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures  ICMJE
 (submitted: April 30, 2008)
Subjects With "Controlled Disease" ("Clear" or "Almost Clear" Disease) According to Investigator's Global Assessment of Disease Severity at Week 8 [ Time Frame: Week 8 ]
Original Primary Outcome Measures  ICMJE Same as current
Change History Complete list of historical versions of study NCT00670241 on ClinicalTrials.gov Archive Site
Current Secondary Outcome Measures  ICMJE
 (submitted: February 14, 2011)
  • Subjects With "Controlled Disease" According to the Investigator's Global Assessment of Disease Severity at Week 4 [ Time Frame: Week 4 ]
  • The Percentage Change in PASI From Baseline to Week 8 [ Time Frame: Baseline, Week 4 and 8 ]
    PASI is Psoriasis Area and Severity Index and is based on the investigator's assessment of extent and severity of the disease. It can range from 0 (best) to 64.8 (worst).
  • Subjects With Relapse During the Study [ Time Frame: Week 8-16 ]
    Among subjects with controlled disease at week 8 relapse was defined as PASI exceeding the baseline PASI value minus 50% of the reduction in PASI obtained from the baseline visit to the last on-treatment visit
  • Subjects With Rebound During the Study [ Time Frame: Week 8-16 ]
Original Secondary Outcome Measures  ICMJE
 (submitted: April 30, 2008)
  • Subjects With "Controlled Disease" According to the Investigator's Global Assessment of Disease Severity at Week 4 [ Time Frame: Week 4 ]
  • The percentage change in PASI from baseline to week 4 and 8 [ Time Frame: Week 4 and 8 ]
  • Subjects with relapse during the study and time to relapse [ Time Frame: Week 8-16 ]
  • Subjedts with rebound during the study [ Time Frame: Week 8-16 ]
Current Other Pre-specified Outcome Measures Not Provided
Original Other Pre-specified Outcome Measures Not Provided
 
Descriptive Information
Brief Title  ICMJE Efficacy and Safety of Calcipotriol Plus Betamethasone Dipropionate Gel Compared With Tacalcitol Ointment and the Gel Vehicle Alone in Patients With Psoriasis Vulgaris
Official Title  ICMJE A Phase 3 Study Comparing a Gel Containing Calcipotriol 50 mcg/g Plus Betamethasone 0.5 mg/g (as Dipropionate) With Tacalcitol Ointment (4 mcg/g) and Gel Vehicle, Used Once Daily in the Treatment of Psoriasis Vulgaris
Brief Summary This study will compare efficacy and safety of once daily treatment of calcipotriol plus betamethasone dipropionate gel (LEO 80185) with tacalcitol ointment and LEO 80185 vehicle alone in subjects with psoriasis vulgaris. Subjects will be treated for up to 8 weeks followed by an observation period of up to 8 weeks to investigate the occurence and the time to relapse and occurence of rebound after discontinuation of the investigational products. Only subjects with "controlled disease" will be considered for this observation phase of the study. "Controlled disease" is defined as "Clear" or "Almost Clear" severity category based on Investigator's global assessment (IGA).
Detailed Description Not Provided
Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 3
Study Design  ICMJE Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single (Investigator)
Primary Purpose: Treatment
Condition  ICMJE Psoriasis Vulgaris
Intervention  ICMJE
  • Drug: calcipotriol and betamethasone (LEO 80185 gel)
    Once daily application
  • Drug: LEO 80185 vehicle
    Once daily application
  • Drug: Tacalcitol ointment
    Once daily application
Study Arms  ICMJE
  • Active Comparator: 1
    Intervention: Drug: calcipotriol and betamethasone (LEO 80185 gel)
  • Active Comparator: 2
    Intervention: Drug: Tacalcitol ointment
  • Placebo Comparator: 3
    Intervention: Drug: LEO 80185 vehicle
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Completed
Actual Enrollment  ICMJE
 (submitted: August 11, 2009)
458
Original Estimated Enrollment  ICMJE
 (submitted: April 30, 2008)
450
Actual Study Completion Date  ICMJE April 2009
Actual Primary Completion Date February 2009   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

  • Signed and dated informed consent to be obtained prior to any trial related procedure, including wash-out
  • Clinical diagnosis of psoriasis vulgaris involving trunk and/or arms and/or legs amenable to treatment with a maximum of 100 g of LEO 80185 gel per week or 10 g per day of tacalcitol ointment
  • Disease severity graded moderate, severe or very severe according to the Investigator's global assessment (IGA) of disease severity
  • A minimum PASI score for extent of 2 in at least one body region (i.e.psoriasis affecting at least 10% of arms, and/or 10% of trunk, and/or 10% of legs)
  • Subjects aged 18 years or above
  • Either sex
  • Any ethnic origin
  • Attending hospital outpatient clinic or the private practice of a dermatologist

Exclusion Criteria:

  • Systemic treatment with biological therapies (marketed or not marketed), with a possible effect on psoriasis vulgaris (e.g., alefacept, efalizumab, etanercept, infliximab, adalimumab) within 3 months prior to randomisation
  • Systemic treatment with all other therapies than biologics, with a possible effect on psoriasis vulgaris (e.g., corticosteroids, retinoids, immunosuppressants) within 4 weeks prior to randomisation
  • Systemic treatment with Vitamin D preparations above 500 IU per day
  • PUVA or Grenz ray therapy within 4 weeks prior to randomization
  • UVB therapy within 2 weeks prior to randomisation
  • Any topical treatment of the trunk/limbs (except for emollients) within 2 weeks prior to randomisation
  • Topical treatment for other relevant skin disorders on the face and flexures (e.g., facial and flexural psoriasis, eczema) with potent or very potent (WHO group III-IV) corticosteroids or vitamin D analogues within 2 weeks prior to randomisation
  • Topical treatment for other relevant skin disorders on the scalp (e.g. scalp psoriasis) with very potent (WHO group IV) corticosteroids or vitamin D analogues within 2 weeks prior to randomisation
  • Planned initiation of, or changes to concomitant medication that could affect psoriasis vulgaris (e.g., beta blockers, ACE inhibitors, anti-malaria drugs, lithium) during the study
  • Current diagnosis of erythrodermic, exfoliative or pustular psoriasis
  • Subjects with any of the following conditions present on the treatment area: viral (e.g., herpes or varicella) lesions, fungal and bacterial skin infections, parasitic infections, skin manifestations in relation to syphilis or tuberculosis, rosacea, perioral dermatitis, acne vulgaris, atrophic skin, striae atro-phicae, fragility of skin veins, ichthyosis, acne rosacea, ulcers and wounds
  • Known or suspected disorders of calcium metabolism associated with hypercalcaemia
  • Known or suspected severe renal insufficiency or severe hepatic disorders
  • Known or suspected hypersensitivity to component(s) of the Investigational Products
  • Current participation in any other interventional clinical study
  • Subjects who have received treatment with any non-marketed drug substance (i.e. an agent which has not yet been made available for clinical use following registration) within the 4-week period prior to randomisation, except for biologics (3 months)
  • Planned exposure to sun during the study that may affect psoriasis vulgaris
  • Previously randomised to this study
  • Subjects known or suspected of not being able to comply with a trial protocol (e.g. due to alcoholism, drug dependency or psychotic state)
  • Females of child-bearing potential wishing to become pregnant during the study, or are breast-feeding, or not using an adequate method of contraception during the study
  • Females of child-bearing potential with positive pregnancy test at Visit 1
Sex/Gender  ICMJE
Sexes Eligible for Study: All
Ages  ICMJE 18 Years and older   (Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE Canada
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT00670241
Other Study ID Numbers  ICMJE LEO 80185-G21
Has Data Monitoring Committee No
U.S. FDA-regulated Product Not Provided
IPD Sharing Statement  ICMJE Not Provided
Responsible Party LEO Pharma
Study Sponsor  ICMJE LEO Pharma
Collaborators  ICMJE Not Provided
Investigators  ICMJE
Principal Investigator: Richard Langley, MD Eastern Canada Cutaneous Research Associates Ltd.
PRS Account LEO Pharma
Verification Date March 2015

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP